Table 3.

Summary of COVID-19 Vaccine Effectiveness in Fully Vaccinated Patients With Cancer

Summary of COVID-19 Vaccine Effectiveness in Fully Vaccinated Patients With Cancer
Study	Country/Countries	Cancer Types	# of Patients or Control	Vaccine	# of Patients or Control	% Seroconversion	Median Titer Level (AU/mL or U/mL)
Gounant et al.61	France	Thoracic	269	Mostly BNT162b2	269	94	4725
		Control	13	BNT162b2	13	—	10,594
Goshen-Lago et al.49	Israel	Various	218	BNT162b2	218	86	—
		Lung cancer	43	BNT162b2	43	86	—
Massarweh et al.50	Israel	Solid cancers	102	BNT162b2	102	90	1931
		Lung cancer	26	BNT162b2	26	92	1334
		Control	78	BNT162b2	78	100	7160
Thakkar et al.51	U.S.	Various	200	BNT162b2	115	95	5173
		Thoracic/head and neck	25	mRNA-1273	62	94	11,963
				Ad26.COV2.S	20	85	1121
		Control	26	—	—	—	>15,000
Addeo et al.52	Switzerland, U.S.	Various	131	BNT162b2	30	93	1232
		Thoracic malignancy	18	mRNA-1273	93	95	2500
Barriere et al.5	France	Solid cancers	42	BNT162b2	42	95	245
		Control	—	BNT162b2	—	100	2517
Monin et al.53	United Kingdom	Various	24	BNT162b2	24	79	—
		Control	12	BNT162b2	12	100	—

Note: Two-dose mRNA vaccines are highly effective (∼90%) in patients with cancer, though patients with cancer have lower titers than health controls.

#, number; AU, arbitrary unit; COVID-19, coronavirus disease 2019; U.S., United States.